HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

On The Cover: Closeup of the RET tyrosine kinase domain ATP-binding cleft (pale pink) occupied by the ZD6474 compound (pink), currently in advanced clinical trials against thyroid cancer. A surface rendering of the ATP pocket is shown indicating a highly complementary fit to ZD6474. The gatekeeper residue of RET is highlighted (yellow). RET is a proto-oncogene frequently activated by mutation or by gene fusion leading to human thyroid cancer such as medullary thyroid carcinoma (background image). For details see the article by Knowles et al., pages 33577–33587.

[Table of Contents]